Details for New Drug Application (NDA): 021253
✉ Email this page to a colleague
NDA 021253 describes ZYPREXA, which is a drug marketed by Cheplapharm and is included in four NDAs. It is available from two suppliers. Additional details are available on the ZYPREXA profile page.
The generic ingredient in ZYPREXA is olanzapine pamoate. There are thirty-three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the olanzapine pamoate profile page.
The generic ingredient in ZYPREXA is olanzapine pamoate. There are thirty-three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the olanzapine pamoate profile page.
Summary for 021253
| Tradename: | ZYPREXA |
| Applicant: | Cheplapharm |
| Ingredient: | olanzapine |
| Patents: | 0 |
Suppliers and Packaging for NDA: 021253
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ZYPREXA | olanzapine | POWDER;INTRAMUSCULAR | 021253 | NDA | Eli Lilly and Company | 0002-7597 | 0002-7597-01 | 1 VIAL in 1 CARTON (0002-7597-01) / 2 mL in 1 VIAL |
| ZYPREXA | olanzapine | POWDER;INTRAMUSCULAR | 021253 | NDA | H2-Pharma LLC | 61269-640 | 61269-640-20 | 1 VIAL in 1 CARTON (61269-640-20) / 2 mL in 1 VIAL |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;INTRAMUSCULAR | Strength | 10MG/VIAL | ||||
| Approval Date: | Mar 29, 2004 | TE: | AP | RLD: | Yes | ||||
Complete Access Available with Subscription
